Herbalife Ltd. Interim CEO John DeSimone filed a Form 4 on November 6, 2026, disclosing the acquisition of 34,593 stock appreciation rights granted on November 4, 2026, under the company's equity incentive plan.

Key Highlights

  • Reporting person: John DeSimone, Interim CEO of Herbalife Ltd. (NYSE:HLF)
  • Grant date: November 4, 2026, with the earliest transaction date listed as 11/04/2026
  • Award size: 34,593 stock appreciation rights (SARs) acquired, coded as transaction type "A" (acquired)
  • Exercise price: $15.31 per SAR, with a price of derivative security listed as $0
  • Vesting schedule: One-third increments on each of November 4, 2027, November 4, 2028, and November 4, 2029, subject to continued service
  • Expiration date: November 4, 2036, with Common Stock as the underlying security
  • Post-transaction holdings: 34,593 derivative securities beneficially owned directly following the reported transaction

DeSimone SAR Grant Details: Herbalife's November 2026 Award

According to the filing, John DeSimone, identified as Interim CEO of Herbalife Ltd., received a grant of 34,593 stock appreciation rights on November 4, 2026. The SARs carry an exercise price of $15.31 and are linked to Herbalife Common Stock as the underlying security. The filing reports a price of derivative security of $0 at the time of the grant. The transaction is recorded in Table II of the Form 4, covering derivative securities.

The filing states that the SARs were "granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan." Per the explanation of responses, the award will vest "in one-third increments on each of November 4th, 2027, November 4th, 2028, and November 4th, 2029, subject to continued service through such date." The SARs are set to expire on November 4, 2036. Following the reported transaction, DeSimone's directly held derivative securities total 34,593, according to the filing.

The Form 4 was signed by Alaaeddine Sahibi as attorney-in-fact for John DeSimone and was filed on November 6, 2026. The filing indicates no non-derivative securities transactions were reported in Table I. No checkbox indicating a Rule 10b5-1(c) plan was marked for this transaction.

What Was Disclosed

Herbalife Ltd. Interim CEO John DeSimone disclosed the acquisition of 34,593 SARs at a $15.31 exercise price, granted November 4, 2026, under the Amended and Restated 2023 Stock Incentive Plan, vesting in thirds through 2029 and expiring in 2036.